410 related articles for article (PubMed ID: 28374073)
21. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.
Joo I; Lee JM; Lee DH; Ahn SJ; Lee ES; Han JK
J Magn Reson Imaging; 2017 Mar; 45(3):731-740. PubMed ID: 27474328
[TBL] [Abstract][Full Text] [Related]
22. Liver Imaging Reporting and Data System: Discordance Between Computed Tomography and Gadoxetate-Enhanced Magnetic Resonance Imaging for Detection of Hepatocellular Carcinoma Major Features.
Chernyak V; Flusberg M; Law A; Kobi M; Paroder V; Rozenblit AM
J Comput Assist Tomogr; 2018; 42(1):155-161. PubMed ID: 28806321
[TBL] [Abstract][Full Text] [Related]
23. Change in Liver Imaging Reporting and Data System Characterization of Focal Liver Lesions Using Gadoxetate Disodium Magnetic Resonance Imaging Compared With Contrast-Enhanced Computed Tomography.
Hope TA; Aslam R; Weinstein S; Yeh BM; Corvera CU; Monto A; Yee J
J Comput Assist Tomogr; 2017; 41(3):376-381. PubMed ID: 27801693
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
25. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
26. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
27. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection.
Chen MF; Ho MC; Kao JH; Hwang RM; Deng SB; Yen KC; Liang PC; Wu CH
J Formos Med Assoc; 2024 Mar; 123(3):318-324. PubMed ID: 38044205
[TBL] [Abstract][Full Text] [Related]
28. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of gadoxetic acid-enhanced MR for small hypervascular hepatocellular carcinoma and the concordance rate of Liver Imaging Reporting and Data System (LI-RADS).
Bae JS; Kim JH; Yu MH; Lee DH; Kim HC; Chung JW; Han JK
PLoS One; 2017; 12(5):e0178495. PubMed ID: 28558068
[TBL] [Abstract][Full Text] [Related]
30. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.
Hong CW; Park CC; Mamidipalli A; Hooker JC; Fazeli Dehkordy S; Igarashi S; Alhumayed M; Kono Y; Loomba R; Wolfson T; Gamst A; Murphy P; Sirlin CB
Eur Radiol; 2019 Sep; 29(9):5073-5081. PubMed ID: 30809719
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
33. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
34. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
35. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
36. Hepatocellular carcinoma with central scar on gadoxetic acid-enhanced and diffusion-weighted magnetic resonance imaging.
Han SB; Kim YK; Min JH; Ha SY; Jeong WK; Lee WJ
Acta Radiol; 2018 Apr; 59(4):393-401. PubMed ID: 28760004
[TBL] [Abstract][Full Text] [Related]
37. Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis.
Park MJ; Kim YK; Lee MH; Lee JH
Acta Radiol; 2013 Mar; 54(2):127-36. PubMed ID: 23148300
[TBL] [Abstract][Full Text] [Related]
38. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features.
Alhasan A; Cerny M; Olivié D; Billiard JS; Bergeron C; Brown K; Bodson-Clermont P; Castel H; Turcotte S; Perreault P; Tang A
Abdom Radiol (NY); 2019 Feb; 44(2):517-528. PubMed ID: 30167771
[TBL] [Abstract][Full Text] [Related]
39. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents.
Santillan C; Fowler K; Kono Y; Chernyak V
Abdom Radiol (NY); 2018 Jan; 43(1):75-81. PubMed ID: 28828680
[TBL] [Abstract][Full Text] [Related]
40. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]